Presentation topics include:
• BioTime’s Products in Development Addressing the Large and Growing Markets in Age-Related Degenerative Disease;
• New Insights into the Fundamental Biology of Human Aging
BioTime, Inc. (NYSE
MKT:BTX) announced that Co-Chief Executive Officer Michael D.
West, Ph.D. delivered a presentation today at “Biomedical
Innovation for Healthy Longevity, International Conference” in St.
Petersburg, Russia.
Dr. West’s presentation is titled “Applied Gerontology: The
Regenerative Medicine Revolution” and describes the application of
BioTime's PureStem® technology for the robust and
reproducible generation of diverse cell types for applications in
aging. The presentation is available on BioTime's website at www.biotimeinc.com.
The four-day conference features scientific leaders from around
the world to discuss recent breakthroughs in understanding the
aging process, as well as companies and institutions focused on
applying the technologies to human aging.
More information on the conference is available at ivaoconf.com.
Background on Regenerative Medicine and Aging
Age-related degenerative diseases are commonly associated with the loss
or dysfunction of the cells in various tissues of the body. The
clocking mechanism for these changes may be the fact that human
cells have a finite capacity to replicate themselves in response
to injury, a phenomenon called the “Hayflick Limit.” Dr. West led
the effort in the mid-1990s that led to the identification of the
immortalizing gene called “telomerase” that could rewind the clock
of cellular aging in human cells. Indeed, the administration of
telomerase allows human cells to escape the Hayflick limit and
replicate indefinitely, a phenomenon designated “cell
immortalization.”
Since that time, BioTime has demonstrated the youthful status of its PureStem® cell types and even the reversal of the developmental aging
of aged human cells by transcriptional reprogramming. It has
emerged as a significant leader in pluripotent cell technology,
with a product pipeline addressing age-related macular
degeneration, orthopedic disorders of aging, age-related metabolic
disorders, as well as other disease applications. A recent open access review
by Dr. West describes the linkage of these insights into human
aging and the strategies to intervene in the biology of human
aging and is available for free download.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from
what we believe to be the world’s premier collection of
pluripotent cell assets. The foundation of our core therapeutic
technology platform is pluripotent cells that are capable of
becoming any of the cell types in the human body. Pluripotent
cells have potential application in many areas of medicine with
large unmet patient needs, including various age-related
degenerative diseases and degenerative conditions for which there
presently are no cures. Unlike pharmaceuticals that require a
molecular target, therapeutic strategies based on the use of pluripotent
cells are generally aimed at regenerating or replacing affected
cells and tissues, and therefore may have broader applicability
than pharmaceutical products.
In order to efficiently advance product candidates through the
clinical trial process, we have historically created operating
subsidiaries for each program and product line. This approach has
fostered efficient use of resources and reduced shareholder
dilution as compared to strategies commonly deployed by the
biotechnology industry, as the various programs and product lines
have advanced through basic research and animal studies. We and
our subsidiaries now have four therapeutic product candidates in
human clinical trials, each of which addresses a large market
opportunity. In addition to the development of therapeutics,
BioTime’s research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic
market opportunities such as cancer diagnostics, drug development
and cell research products, and mobile health software
applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated
together with the many uncertainties that affect the business of
BioTime and its subsidiaries, particularly those mentioned in the
cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click
on the following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com:
or
or
No comments:
Post a Comment